- Home
- JWEL vs SONN Comparison
JWEL vs SONN Comparison
Compare JWEL & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- SONN
- Stock Information
- Founded
- JWEL 2012
- SONN N/A
- Country
- JWEL China
- SONN United States
- Employees
- JWEL N/A
- SONN N/A
- Industry
- JWEL Other Consumer Services
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- SONN Health Care
- Exchange
- JWEL Nasdaq
- SONN Nasdaq
- Market Cap
- JWEL 4.1M
- SONN 3.3M
- IPO Year
- JWEL 2021
- SONN N/A
- Fundamental
- Price
- JWEL $1.95
- SONN $3.02
- Analyst Decision
- JWEL
- SONN Strong Buy
- Analyst Count
- JWEL 0
- SONN 3
- Target Price
- JWEL N/A
- SONN $117.33
- AVG Volume (30 Days)
- JWEL 16.1K
- SONN 1.3M
- Earning Date
- JWEL 11-29-2024
- SONN 12-12-2024
- Dividend Yield
- JWEL N/A
- SONN N/A
- EPS Growth
- JWEL N/A
- SONN N/A
- EPS
- JWEL N/A
- SONN N/A
- Revenue
- JWEL $160,009,293.00
- SONN $55,881.00
- Revenue This Year
- JWEL N/A
- SONN N/A
- Revenue Next Year
- JWEL N/A
- SONN N/A
- P/E Ratio
- JWEL N/A
- SONN N/A
- Revenue Growth
- JWEL N/A
- SONN N/A
- 52 Week Low
- JWEL $1.00
- SONN $2.85
- 52 Week High
- JWEL $3.14
- SONN $18.72
- Technical
- Relative Strength Index (RSI)
- JWEL 54.81
- SONN 25.74
- Support Level
- JWEL $1.81
- SONN $2.85
- Resistance Level
- JWEL $2.15
- SONN $10.02
- Average True Range (ATR)
- JWEL 0.18
- SONN 0.81
- MACD
- JWEL 0.01
- SONN -0.11
- Stochastic Oscillator
- JWEL 49.09
- SONN 2.37
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.